Hangzhou Biotest Biotech Co.,Ltd. (SHA:688767)

Market Cap	5.70B -0.6%
Revenue (ttm)	459.42M -7.3%
Net Income	20.30M -81.5%
EPS	0.15 -77.7%
Shares Out	146.32M
PE Ratio	255.90
Forward PE	n/a
Dividend	0.70 (1.67%)
Ex-Dividend Date	Jun 1, 2026

Volume	1,846,698
Open	38.57
Previous Close	38.95
Day's Range	37.61 - 38.97
52-Week Range	30.40 - 50.98
Beta	0.65
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 29, 2026

About Hangzhou Biotest Biotech

Hangzhou Biotest Biotech Co.,Ltd. engages in the research and development, manufacture, sale, and service of in vitro diagnostic assays and reagents, and instruments in China and internationally. The company offers medical test products for fertility health, cardiology, oncology, inflammation, veterinary test, drug of abuse, infectious diseases, and other diagnostic rapid test. It also provides microfluidic immunofluorescence analysis system; Diagpal SE lateral flow reader, a drug tester; and Diagpal lateral flow reader, a clear image of the te...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 613
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688767

Financial Performance

In 2025, Hangzhou Biotest Biotech's revenue was 448.01 million, a decrease of -19.91% compared to the previous year's 559.40 million. Earnings were 49.25 million, a decrease of -70.94%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 2, 2026

Data Sources Report a data error